The two-year grant supports the essential research required to file an Investigational New Drug application, moving the experimental therapy closer to human clinical trials. Saros Therapeutics focuses on a nanoparticle system that delivers compounds directly to immune cells, potentially addressing metastatic cancers that remain resistant to current checkpoint inhibitors. Recent findings regarding their SMP technology appeared in the journal Science earlier this year.
In section Releases
Saros Therapeutics Secures $2 Million NCI Grant for Immunotherapy
A startup housed within Rosalind Franklin University’s Helix 51 incubator has landed a second $2 million Phase II award from the National Cancer Institute. The funding accelerates development of a nanoparticle platform designed to bypass tumor defenses by triggering the body’s innate immune system through the STING pathway.
Following the award, the company plans to scale its operations within the university’s Innovation and Research Park. CEO Matt Britz noted that the formulation is engineered to enhance immune activation while enabling intravenous administration for systemic treatment. Janice Urban, interim executive vice president for research at the university, highlighted the importance of this validation for the startup’s delivery system. The company aims to overcome the safety and efficacy limitations of previous immunotherapy approaches by precisely targeting the STING pathway.
Comments (0)
No comments yet. Be the first!